Moderate-to-severe atopic dermatitis is associated with negative impacts on quality of life and health outcomes in all age groups, with the impact on children and families being uniquely severe. However, the rapid pace of drug development and uncertainty around novel medications may impact the shared decision-making process and lead to suboptimal treatment of many children. Thus, educating pediatric dermatologists and allergists is critical to positively affect treatment decisions and improve long-term outcomes. In addition, engaging experts in pediatric dermatology and allergy to consider what are the most important research issues in atopic dermatitis is important to direct future efforts. To address this need and help fill the gap left by canceled conferences in 2020, PeDRA is conducting a six-part educational series Emerging Therapies for Moderate-to-Severe Atopic Dermatitis in Children.
Being hosted by distinguished faculty in pediatric dermatology and allergy/immunology, this non-CME program will include a total of six parts, including two webinars, two podcasts, and two virtual meetings/townhalls.
Part 1: PEDIATRIC ATOPIC DERMATITIS – New and Emerging Systemic Therapies: An Overview
RECORDED LIVE: Tuesday, October 6, 2020, 5:15 – 6:15PM PDT / 8:15 – 9:15PM EDT
Chair: Lawrence Eichenfield, MD
Speakers: Megha Tollefson, MD and Bob Geng, MD
Panel: Wynnis Tom, MD and Dawn Davis, MD
View Full Agenda
5:15 – 5:20 – Introduction
5:20 – 5:37 – Biologics – Overview and translation to practice
5:37 – 5:49 – JAK-inhibitors
5:49 – 6:01 – Mechanisms of action and allergy perspectives
6:01 – 6:15 – Moderated discussion with audience
Part 2: PEDIATRIC ATOPIC DERMATITIS – Algorithms of the Future
RECORDED LIVE: Tuesday, October 13, 2020, 5:15 – 6:15PM PDT / 8:15 – 9:15PM EDT
Chair: Lawrence Eichenfield, MD
Speakers: Dawn Davis, MD and Wynnis Tom, MD
Panel: Megha Tollefson, MD and Bob Geng, MD
View Full Agenda
5:15 – 5:20 – Introduction
5:20 – 5:32 – New topicals for moderate to severe disease
5:32 – 5:42 – New and traditional systemics: where do they fit?
5:42 – 6:00 – Considerations when selecting appropriate therapy for the appropriate patient
6:00 – 6:15 – Interactive discussion on “hot” research issues in moderate to severe atopic dermatitis for pediatric dermatologists and allergists
Part 3: Systemic Therapy for Moderate-to-Severe AD in Children: Where are We?
AVAILABLE NOW
Host: Lawrence Eichenfield, MD
Guests: Dawn Davis, MD, Bob Geng, MD, and Wynnis Tom, MD
Guests
Part 4: Systemic Therapy for Moderate-to-Severe AD in Children: Where are We?
Tuesday, December 8, 2020 5:15 – 6:15PM PST / 8:15 – 9:15PM EST
Host: Lawrence Eichenfield, MD
Guests: Dawn Davis, MD, Bob Geng, MD, and Wynnis Tom, MD
Special Guests: Emma Guttman-Yassky, MD, PhD and Eric Simpson, MD
Part 5: Patient Perspectives on Therapies for Moderate-to-Severe AD in Children
AVAILABLE NOW
Host: Dawn Davis, MD
Special Guests: Charlene Miciano and Sarah Pry
Part 6: Patient Perspectives on Therapies for Moderate-to-Severe AD in Children
Tuesday, January 5, 2021, 5:15 – 6:15PM PST / 8:15 – 9:15PM EST
An open discussion with faculty and patient advocates in follow-up to the second podcast. Bring your questions or just listen in.
Host: Dawn Davis, MD
Guests: Lawrence Eichenfield, MD, Bob Geng, MD, and Wynnis Tom, MD
Special Guests: Korey Capozza, MPH from Global Parents for Eczema Research and Wendy Smith Begolka, MBS from the National Eczema Association
FACULTY
Lawrence Eichenfield, MD
Chair
Professor of Dermatology and Pediatrics
Chief, Pediatric and Adolescent Dermatology
Vice Chair, Department of Dermatology
University of California, San Diego and Rady Children’s Hospital, San Diego
Bob Geng, MD
Assistant Professor of Medicine and Pediatrics
Divisions of Adult and Pediatric Allergy & Immunology
Co-Director of the Allergy Asthma Foundation of America sponsored UCSD Pediatric Severe Asthma Program
Allergy/Immunology Director of the Multidisciplinary Atopic Dermatitis Program
University of California, San Diego and Rady Children’s Hospital, San Diego
Dawn Davis, MD
Professor of Dermatology and Pediatrics
Division Chair, Clinical Dermatology
Director, Section of Pediatric Dermatology
Mayo Clinic Rochester
Megha Tollefson, MD
Associate Professor of Dermatology and Pediatrics
Consultant, Dermatology
Consultant, Pediatric and Adolescent Medicine
Mayo Clinic Rochester
Wynnis Tom, MD
Clinical Professor of Dermatology and Pediatrics
Fellowship Program Director
Pediatric & Adolescent Dermatology
University of California, San Diego and Rady Children’s Hospital, San Diego
SPECIAL GUESTS
Emma Guttman-Yassky, MD, PhD
Vice Chair for Research
Incoming System Chair of the Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
Charlene Miciano
Charlene is a college student from San Diego majoring in bioinformatics. Her experience with eczema growing up influenced her to become an ambassador for the National Eczema Association. When she’s not coding, she enjoys music in many forms, whether it be playing piano or ukulele, doing karaoke, or going to concerts.
Korey Capozza, MPH
Korey is the founder and executive director of Global Parents for Eczema Research and the mother of a child with moderate to severe eczema. Her professional background is in public health, collaborative leadership, and patient-centered research.
Eric Simpson, MD
Professor of Dermatology
Oregon Health and Science University
Sarah Pry
Sarah is a mother of 2, Aiden age 12 and Bayle age 8. Aiden has severe eczema. Sarah works full time as an insurance agent in TN and in what spare time she has as a mom, she plays with her kids. She also loves to advocate and learn from the experts by volunteering or helping anyway that she can.
Wendy Smith Begolka, MBS
Ms. Smith Begolka is the VP for Scientific and Clinical Affairs for the National Eczema Association (NEA) where she guides the evolution and growth of NEA’s patient-centric research and clinical care efforts across the organization and with diverse stakeholders. Prior to joining NEA in 2018, she conducted biomedical laboratory research investigating immunological pathways of autoimmune disease at Northwestern University, and for over a decade, led the development of American Academy of Dermatology clinical guidelines and the application of science to the intersecting areas of quality, education, and advocacy. Her 25+ year scientific career has focused on advancing research, the use of scientific discovery and findings to support improved therapeutic options and clinical care, and the translation of research data for educational, quality, advocacy, and policy initiatives.
Special thanks to Pfizer Inc. for their support of this independent medical education program. PeDRA is solely responsible for all program content and the selection of all presenters, authors, moderators, and faculty.
